HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency.

AbstractBACKGROUND:
Determining the presence and extent of co-morbidities is fundamental in assessing patients with chronic respiratory disease, where increased cardiovascular risk, presence of osteoporosis and low muscle mass have been recognised in several disease states. We hypothesised that the systemic consequences are evident in a further group of subjects with COPD due to Alpha-1 Antitrypsin Deficiency (A1ATD), yet are currently under-recognised.
METHODS:
We studied 19 patients with PiZZ A1ATD COPD and 20 age, sex and smoking matched controls, all subjects free from known cardiovascular disease. They underwent spirometry, haemodynamic measurements including aortic pulse wave velocity (aPWV), an independent predictor or cardiovascular risk, dual energy X-ray absorptiometry to determine body composition and bone mineral density.
RESULTS:
The aPWV was greater in patients: 9.9(2.1) m/s than controls: 8.5(1.6) m/s, p = 0.03, despite similar mean arterial pressure (MAP). The strongest predictors of aPWV were age, FEV1% predicted and MAP (all p < 0.01). Osteoporosis was present in 8/19 patients (2/20 controls) and was previously unsuspected in 7 patients. The fat free mass and bone mineral density were lower in patients than controls (p < 0.001).
CONCLUSIONS:
Patients with A1ATD related COPD have increased aortic stiffness suggesting increased risk of cardiovascular disease and evidence of occult musculoskeletal changes, all likely to contribute hugely to overall morbidity and mortality.
AuthorsJames M Duckers, Dennis J Shale, Robert A Stockley, Nichola S Gale, Bronwen A J Evans, John R Cockcroft, Charlotte E Bolton
JournalRespiratory research (Respir Res) Vol. 11 Issue 1 Pg. 173 (Dec 07 2010) ISSN: 1465-993X [Electronic] England
PMID21138571 (Publication Type: Journal Article)
Topics
  • Age Distribution
  • Cardiovascular Diseases (mortality)
  • Comorbidity
  • Female
  • Humans
  • Joint Diseases (mortality)
  • Male
  • Middle Aged
  • Prevalence
  • Pulmonary Disease, Chronic Obstructive (mortality)
  • Risk Assessment
  • Risk Factors
  • Sex Distribution
  • Survival Analysis
  • Survival Rate
  • United Kingdom (epidemiology)
  • alpha 1-Antitrypsin Deficiency (mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: